RxDoctor Payments Data

William Yao, MD

Otolaryngology · Houston, TXNPI 1831429893

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Optinose US, Inc. at 50.9% of the total. Reporting peaked in 2023 at $36,947 and has fallen 50.8% since, to $18,168 in 2025. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$153,684in general payments, 2019–2025

Across 319 payments — averaging $481.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$78K
  • Acclarent, Inc$22K
  • Aerin Medical Inc.$19K
  • Sanofi$18K
  • Stryker$6K
  • Medtronic$5K
  • plus $5K from 12 others
$125,848in research payments, 2019–2025

Across 20 payments — averaging $6292.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aerin Medical Inc.$90K
  • Optinose US, Inc.$36K

What the payments were for

  • Consulting fees$60,55339%
  • Speaking & faculty fees$65,92543%
  • Travel & lodging$13,9379%
  • Food & beverage$13,2699%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,684 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas

Medicare billing

Part B allowed, 2024
$73,400
Medicare patients
102
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab19$69,519
Ipratropium Bromide85$1,912
Fluticasone Propionate115$1,583
Azelastine Hcl49$1,216
Clarithromycin19$756
Pantoprazole Sodium36$621
Montelukast Sodium31$472
Methylprednisolone61$406
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav39$241
Famotidine28$224
Diclofenac Sodium44$184
Mupirocin26$179
Clindamycin Hcl22$166
Levofloxacin32$154
Prednisone49$103

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →